Archive for category: News

Bengaluru: Sakra World Hospital, a pioneering healthcare facility in India funded entirely by foreign direct investment (FDI), has successfully completed 100 robotic gastrointestinal (GI) surgeries.

In the medical field, robotic-assisted surgical procedures are steadily on the rise. The increasing acceptance of robotic surgeries can be attributed to their accuracy, minimally invasive techniques, and capacity to improve surgical outcomes. With a group of skilled surgeons and cutting-edge facilities, Sakra World Hospital has become a pioneer in leveraging this technology to help patients suffering from gastrointestinal surgical issues.

“We take immense pride in reaching a significant milestone in robotic GI surgeries, underscoring the skill and commitment of our proficient surgical team,” lauded Lovekesh Phasu, Chief Operating Officer, Sakra World Hospital, Bengaluru, adding, “At Sakra, we’re committed to setting high standards and achieving them, to benefit our patients and provide quality healthcare for all.”

The application of robot-assisted technologies has greatly improved surgical capabilities in GI surgeries. These systems are operated directly by surgeons, in contrast to autonomous systems, which enable careful dissection around target organs. Although laparoscopic surgery provides benefits such as accurate dissection under high-resolution imaging and minimally invasive procedures, it has limitations due to the limited dexterity of the instruments. These limitations are overcome by the existing robotic system’s articulated instruments, vibration filtering, and motion scaling functions. These capabilities allow surgeons to perform more versatile surgeries than they could with the standard laparoscopic equipment.

Moreover, the robotic system’s instruments with wrist-like movements and dexterity assures delicate tissue handling and precision surgery with minimal bleeding. This capability, coupled with three-dimensional magnified, enhanced imaging, provides a platform wherein complex procedures in critical places and organs can be safely performed. Through these innovations, robotics surgery in the gastrointestinal realm continues to push boundaries, enhancing surgical precision and expanding treatment options for patients.

Robotic GI surgery has emerged as a reassuring alternative to traditional methods, dispelling common fears. The robotic system not only provides surgeons with better visualization and precision, but the patient also benefits from smaller incisions, less blood loss, quicker recovery, and reduced post-operative pain.

“The completion of 100 robotic GI surgeries at Sakra World Hospital not only marks a numerical achievement, but also serves as evidence of the hospital’s steadfast dedication to delivering top-notch care to its patients,” remarked Dr Sadiq Saleem Sikora, Director of Gastrointestinal Surgery and Liver Transplantation at Sakra World Hospital, Bengaluru.

“We are thrilled to partner with an organization that shares our dedication to delivering transformative medicines to patients with significant unmet need,” said John Houston, Ph.D., Chairperson, President and Chief Executive Officer of Arvinas. “We believe the expertise and scale of Novartis will broaden the development of ARV-766 and its potential to be a first- and best-in-class treatment for patients with prostate cancer. This strategic transaction also further validates our innovative PROTAC protein degrader platform and its potential to deliver new treatments.”

Under the terms of the transaction agreements, Novartis will be responsible for worldwide clinical development and commercialization of ARV-766 and will have all research, development, manufacturing, and commercialization rights with respect to the preclinical AR-V7 program. Arvinas will receive an upfront payment in the aggregate amount of $150.0 million. Under the License Agreement, Arvinas is eligible to receive additional development, regulatory, and commercial milestones of up to $1.01 billion, as well as tiered royalties for ARV-766.

Closing of the transaction is subject to the parties’ receipt of any necessary consents or approvals, including the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. Goldman Sachs & Co. LLC is acting as the exclusive financial advisor to Arvinas.

ARV-766 is an investigational orally bioavailable PROTAC protein degrader designed to selectively target and degrade the androgen receptor (AR). Preclinically, ARV-766 has demonstrated activity in models of wild type androgen receptor tumors in addition to tumors with AR mutations or amplification, both common potential mechanisms of resistance to currently available AR-targeted therapies.

Arvinas is a clinical-stage biotechnology company. Arvinas uses its proprietary PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its preclinical pipeline of PROTAC protein degraders against validated and “undruggable” targets, the company has four investigational clinical-stage programs: vepdegestrant (ARV-471) for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-766 and bavdegalutamide for the treatment of patients with metastatic castration-resistant prostate cancer; and ARV-102 for the treatment of patients with neurodegenerative disorders.

Consuming sugar-sweetened drinks in the first few years of childhood can be linked to poor diet patterns that increase the risk of obesity in later life, according to a new study by the School of Psychology at Swansea University.

Published in the European Journal of Clinical Nutrition, the study tracked the influence of diet on 14,000 British children from birth to adulthood and is believed to be the longest of its kind ever reported.

Using the Avon Longitudinal Study of Parents and Children, the research team found:

Children who drank fizzy drinks such as cola or sugar-sweetened fruit cordials before the age of two gained more weight when they were 24 years old. Girls who had pure fruit juice gained less weight, while the weight of boys remained the same.

At three years of age, toddlers who drank cola consumed more calories, fat, protein, and sugar but less fibre. In contrast, those given pure apple juice consumed less fat and sugar but higher amounts of fibre.

The study also highlighted corresponding differences in food choices. Children who consumed pure apple juice often followed a diet with more fish, fruit, green vegetables, and salad, whereas those drinking cola ate more burgers, sausages, pizza, french fries, meat, chocolate, and sweets.

Additionally, the team discovered a link between sugar-sweetened drinks and social deprivation, with children from affluent backgrounds more likely to have access to pure fruit juice.

Lead researcher Professor David Benton said: “The early diet establishes a food pattern that influences, throughout life, whether weight increases. The important challenge is to ensure that a child develops a good dietary habit: one that offers less fat and sugar, although pure fruit juice, one of your five a day, adds vitamin C, potassium, folate, and plant polyphenols.”

Dr Hayley Young added: “Obesity is a serious health concern, one that increases the risk of many other conditions. Our study shows that the dietary causes of adult obesity begin in early childhood and that if we are to control it, more attention needs to be given to our diet in the first years of life.”

References: Benton, D., Young, H.A. Early exposure to sugar sweetened beverages or fruit juice differentially influences adult adiposity. Eur J Clin Nutr (2024). https://doi.org/10.1038/s41430-024-01430-y